« Back

Qingjie Li, Ph.D.
Assistant Professor, Division of Gastroenterology and Hepatology



Qingjie Li, Ph.D.

Qingjie Li, Ph.D.
Assistant Professor
Department of Internal Medicine

University of Texas Medical Branch
301 University Blvd.
Galveston, TX 77555-0764
Phone: 409.772.1501
Fax: 409.772.5841
quli@utmb.edu

Biosketch

Dr. Li received a M.S. in Organic Chemistry in 1991 and a Ph.D. in Biochemistry and Molecular Biology in 2000. He received his postdoctoral training in Dr. Dashwood's laboratory at the Linus Pauling Institute, Oregon State University, where he worked on molecular mechanisms and chemoprevention of colorectal cancer. His significant finding that AP-2α associates with APC/ß-Catenin provided extremely exciting leads on the role of AP-2α as a tumor suppressor in the colon. His in vivo studies showed that AP-2α dramatically inhibited intestinal tumor formation in Apc(min) mice, a widely used animal model of polyp formation in the gut, suggesting AP-2α as a target of considerable promise in colon cancer gene therapy. Dr. Li joined UTMB in 2006 as an Assistant Professor. He is the first to identify myosin regulatory light chain (RLC) as a nuclear factor that tethers to DNA, modulates gene transcription and controls homeostasis in the gut.

Research Interests

Dr. Li's primary research interests include (i) genetic and epigenetic mechanisms of inflammatory bowel diseases (IBD), especially nuclear functions of RLC and epigenetic regulation of 1C subunit of Cav1.2 calcium channel in response to colonic inflammation; (ii) identification of therapeutic targets for inflammatory bowel diseases; (iii) ICAM-1 in signal transduction pathways through outside-in signaling events; (iv) molecular mechanisms, chemoprevention and gene therapy of colitis-associated colorectal cancer.

Selected Publications

  1. Li QJ, Sarna SK. Chronic stress targets posttranscriptional mechanisms to rapidly upregulate α1C-subunit of Cav1.2b calcium channels in colonic smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 2011; 300:G154-63.
  2. Li QJ, Löhr CV, Dashwood RH. Activator protein 2alpha suppresses intestinal tumorigenesis in the Apc(min) mouse. Cancer Lett 2009; 283: 36-42.
  3. Li QJ, Sarna SK. Nuclear myosin II regulates the assembly of preinitiation complex for ICAM-1 gene transcription. Gastroenterology 2009; 137:1051-1060.
  4. Li QJ, Dashwood WM, Zhong X, Nakagama H, Dashwood RH. Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving beta-catenin, c-Myc and E2F1. Oncogene 2007; 26: 6194-202.
  5. Li QJ, Dashwood RH. Activator protein 2a associates with adenomatous polyposis coli/b-catenin and inhibits ß-catenin/T-cell factor transcriptional activity in colorectal cancer cells. J Biol Chem 2004; 279: 45669-45675.
  6. Li QJ, Dashwood WM, Zhong XY, Al-Fageeh M, Dashwood RH. Cloning of the Rat ß-Catenin Gene (Ctnnb1) Promoter, and its Functional Analysis Compared with Catnb and CTNNB1 Promoters. Genomics 2004; 83: 231-242.
  7. Al-Fageeh M, Li QJ, Dashwood WM, Myzak MC, Dashwood RH. Phosphorylation and ubiquitination of oncogenic mutants of b-catenin containing substitutions at Asp32. Oncogene 2004; 23: 4839-4846.
  8. Di¬az GD, Li QJ, Dashwood RH. Caspase-8 and AIF mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin. Cancer Res 2003; 63: 1254-1261.
  9. ΛιΘςονΒΜ,Αλ–ΦαγεεηΜ,ΒλυμΧΑ.,ΔασηωοοδΡΗ.Σεθυενχινγ ο τηερατ ß-catenin gene (Ctnnb1) and mutational analysis of liver tumors induced by 2-amino-3-methylimidazo[4,5-f]quinoline. Gene 2002; 283: 255-262.
  10. Li QJ, Xie P, Huang JJ, Gu YP, Zeng WM, Song HP. Polymorphisms and functions of the aldose reductase gene 5' regulatory region in Chinese patients with type 2 diabetes mellitus. Chinese Med J 2002; 115: 205-213.

»Pub Med Search

The department of internal medicine is developing evidence based clinical protocols which will be available in EPIC (as order sets) for use when admitting patients with these diagnoses. Their AIM is to standardize care and decrease length of stay and readmission rates.

Currently available protocols are:
  • CAP - Community Acquired Pneumonia Orderset
  • Congestive Heart Failure (CHF)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Diabetic Ketoacidosis Adult, ICU
  • General Medicine Admission
  • Immunodeficiency Flow Panel
  • MICU/CCU Admission Order Set
  • Oral Analgesic Medicaitons
  • Parenteral Opioids
  • Sepsis, Adult ICU
  • 111 - Stroke Alert
  • 112 - Stroke Activation
  • 300086 - Stroke Floor Admission
  • 3000000001 -  Stroke Critical care without tPA
  • 300088 Stroke - Transfer from Critical care to floor
  • 3004002 - Stroke Discharge

All protocols can be found in the EPIC order set section.

» For more information

Meaning Use logo

The department of Internal Medicine has a large role in the Meaningful Use Initiative. Our participation is key for the success of the initiative. Please visit the meaningful use website for important communication and updates from the Meaningful Use Initiative.

Site Managed by UTMB Information Design Services.